Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)
NCT00634400 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6268
Last updated 2011-01-25
Summary
A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function
Conditions
- Congestive Heart Failure
Interventions
- DRUG
-
Candesartan
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Chris Granger, MD
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-03-31
- Primary Completion
- 2003-05-31
- Completion
- 2003-05-31
More Related Trials
-
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
NCT00607633 ·Status: COMPLETED
-
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
NCT00242346 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
NCT02884206 ·Status: COMPLETED ·Phase: PHASE3
-
Candesartan in the Prevention of Relapsing Atrial Fibrillation
NCT00130975 ·Status: COMPLETED ·Phase: PHASE3
-
Atacand (Candesartan) Real Life Study
NCT00620178 ·Status: COMPLETED
-
The Potential of Candesartan to Retard the Progression of Aortic Stenosis
NCT00699452 ·Status: UNKNOWN ·Phase: PHASE3
-
Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker
NCT01444833 ·Status: UNKNOWN ·Phase: NA
-
Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension
NCT01152567 ·Status: COMPLETED
-
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
NCT00434967 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Valsartan Administered Once Daily Versus Twice Daily, in Patients With Stable, Chronic Heart Failure
NCT00294086 ·Status: COMPLETED ·Phase: PHASE2
-
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
NCT00608153 ·Status: COMPLETED
-
Candesartan Effect in Second Stage Arterial Hypertension
NCT00621153 ·Status: COMPLETED ·Phase: PHASE4
-
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
NCT00244621 ·Status: COMPLETED ·Phase: PHASE3
-
A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323
NCT02094924 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension
NCT01012479 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
NCT00853658 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control
NCT02521246 ·Status: WITHDRAWN ·Phase: PHASE3
-
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
NCT01289132 ·Status: COMPLETED ·Phase: PHASE2
-
CKD-330 Drug-Drug Interaction Study (Candesartan)
NCT02064621 ·Status: COMPLETED ·Phase: PHASE1
-
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
NCT00383929 ·Status: COMPLETED ·Phase: PHASE3
-
Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions
NCT02006602 ·Status: COMPLETED ·Phase: PHASE1
-
The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure
NCT00241098 ·Status: COMPLETED ·Phase: PHASE4
-
Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)
NCT00108706 ·Status: UNKNOWN ·Phase: PHASE4
-
Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.
NCT05848206 ·Status: COMPLETED
-
Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
NCT00775814 ·Status: COMPLETED ·Phase: PHASE4